Dr. Ian Kelleher (University of Edinburgh, Scotland) joins AJP Audio to discuss an emulated target trial looking at the prophylactic qualities of doxycycline, an antibiotic, in an adolescent population at risk to develop schizophrenia spectrum disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin joins the podcast to put the rest of the issue into context.

00:53 Doxycycline and the risk of developing schizophrenia
04:03 Emulated target trials versus randomized control trials
06:43 Methods of action
09:24 Dosage and exposure levels for doxycycline
10:15 Immediate clinical applications
10:56 Limitations of the study
11:33 Future research
12:43 Kalin interview
13:00 Lång et al.
19:43 Zhao et al.
25:20 Metrik et al.

Transcript

Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

Subscribe to the podcast here.

Listen to other podcasts produced by the American Psychiatric Association.

Browse articles online.

How authors may submit their work.

Follow the journals of APA Publishing on Twitter.

E-mail us at ajp@psych.org

00:53 Doxycycline and the risk of developing schizophrenia
04:03 Emulated target trials versus randomized control trials
06:43 Methods of action
09:24 Dosage and exposure levels for doxycycline
10:15 Immediate clinical applications
10:56 Limitations of the study
11:33 Future research
12:43 Kalin interview
13:00 Lång et al.
19:43 Zhao et al.
25:20 Metrik et al.